Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 23Sarcoma 5Lymphoid 2Gastrointestinal 1Dermatologic 1

Conditions

Lymphoma 16Central Nervous System Neoplasms 9Lymphoma, Follicular 5Astrocytoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Glioblastoma 4Lymphoma, Non-Hodgkin 3Glioma 3Recurrence 2Oligodendroglioma 2Neuroectodermal Tumors, Primitive 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Gliosarcoma 2Glioma, Subependymal 2Ependymoma 2Burkitt Lymphoma 2Brain Neoplasms 2Blast Crisis 2Triple Negative Breast Neoplasms 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Meningioma 1Medulloblastoma 1

Interventions

Cyclophosphamide 100Rituximab 82fludarabine phosphate 46Peripheral Blood Stem Cell Transplantation 45fludarabine 43Lenalidomide 35Filgrastim 33Methotrexate 32Cytarabine 32Busulfan 32Etoposide 31venetoclax 30Cyclosporine 30Dexamethasone 29Radiotherapy 28Mycophenolic Acid 28Melphalan 28Bendamustine Hydrochloride 25Antilymphocyte Serum 25Vincristine 24Gemcitabine 24ibrutinib 22Whole-Body Irradiation 22Doxorubicin 20Tacrolimus 19Methylprednisolone 18Bortezomib 18Brentuximab Vedotin 16pembrolizumab 15Prednisone 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Temozolomide × Lymphoid × Clear all
NCT06208657 2026-01-28

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Australian & New Zealand Children's Haematology/Oncology Group

Phase 1/2 Recruiting
90 enrolled
CNSLymphoid

Lymphoma, Neoplasms, Recurrence, Central Nervous System Neoplasms

NCT01235793 2018-11-20

DRBEAT

Cedars-Sinai Medical Center

Phase 2 Terminated
11 enrolled 10 charts
Lymphoid

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡